KR970010752A - 치환아미딘유도체 또는 그 약학적으로 허용되는 염 및 그것을 함유하는 혈소판 응집저해제 - Google Patents

치환아미딘유도체 또는 그 약학적으로 허용되는 염 및 그것을 함유하는 혈소판 응집저해제 Download PDF

Info

Publication number
KR970010752A
KR970010752A KR1019960037444A KR19960037444A KR970010752A KR 970010752 A KR970010752 A KR 970010752A KR 1019960037444 A KR1019960037444 A KR 1019960037444A KR 19960037444 A KR19960037444 A KR 19960037444A KR 970010752 A KR970010752 A KR 970010752A
Authority
KR
South Korea
Prior art keywords
pharmaceutically acceptable
acceptable salt
carbon atoms
substituted
group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
KR1019960037444A
Other languages
English (en)
Other versions
KR100225698B1 (ko
Inventor
히로유키 야미시타
쿠니오 오쿠무라
토시유키 시마자키
아키히토 카네마쯔
요지 아오키
유키 나카지마
코오헤이 야자와
켄지 키바야시
Original Assignee
사토 아키오
미쯔이도오아쯔가가꾸 가부시기가이샤
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 사토 아키오, 미쯔이도오아쯔가가꾸 가부시기가이샤 filed Critical 사토 아키오
Publication of KR970010752A publication Critical patent/KR970010752A/ko
Application granted granted Critical
Publication of KR100225698B1 publication Critical patent/KR100225698B1/ko
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/36—Radicals substituted by singly-bound nitrogen atoms
    • C07D213/40—Acylated substituent nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C257/00—Compounds containing carboxyl groups, the doubly-bound oxygen atom of a carboxyl group being replaced by a doubly-bound nitrogen atom, this nitrogen atom not being further bound to an oxygen atom, e.g. imino-ethers, amidines
    • C07C257/10—Compounds containing carboxyl groups, the doubly-bound oxygen atom of a carboxyl group being replaced by a doubly-bound nitrogen atom, this nitrogen atom not being further bound to an oxygen atom, e.g. imino-ethers, amidines with replacement of the other oxygen atom of the carboxyl group by nitrogen atoms, e.g. amidines
    • C07C257/18—Compounds containing carboxyl groups, the doubly-bound oxygen atom of a carboxyl group being replaced by a doubly-bound nitrogen atom, this nitrogen atom not being further bound to an oxygen atom, e.g. imino-ethers, amidines with replacement of the other oxygen atom of the carboxyl group by nitrogen atoms, e.g. amidines having carbon atoms of amidino groups bound to carbon atoms of six-membered aromatic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C257/00—Compounds containing carboxyl groups, the doubly-bound oxygen atom of a carboxyl group being replaced by a doubly-bound nitrogen atom, this nitrogen atom not being further bound to an oxygen atom, e.g. imino-ethers, amidines
    • C07C257/10—Compounds containing carboxyl groups, the doubly-bound oxygen atom of a carboxyl group being replaced by a doubly-bound nitrogen atom, this nitrogen atom not being further bound to an oxygen atom, e.g. imino-ethers, amidines with replacement of the other oxygen atom of the carboxyl group by nitrogen atoms, e.g. amidines
    • C07C257/20—Compounds containing carboxyl groups, the doubly-bound oxygen atom of a carboxyl group being replaced by a doubly-bound nitrogen atom, this nitrogen atom not being further bound to an oxygen atom, e.g. imino-ethers, amidines with replacement of the other oxygen atom of the carboxyl group by nitrogen atoms, e.g. amidines having nitrogen atoms of amidino groups acylated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/02—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines
    • C07D217/04—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines with hydrocarbon or substituted hydrocarbon radicals attached to the ring nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
    • C07D295/18—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carboxylic acids, or sulfur or nitrogen analogues thereof
    • C07D295/195—Radicals derived from nitrogen analogues of carboxylic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D307/38—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D307/52—Radicals substituted by nitrogen atoms not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
    • C07D311/58—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring other than with oxygen or sulphur atoms in position 2 or 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D333/30—Hetero atoms other than halogen
    • C07D333/36—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
    • C07D407/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Treatment Of Sludge (AREA)
  • Separation Of Suspended Particles By Flocculating Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

본 발명은 강력한 혈소판응집저해작용을 가지고, 경구투여에서의 유효성에 뛰어난 신규의 화합물을 제공하는 것을 목적으로 한 것이며, 상기 신규의 화합물이 하기 일반식(1)로 표시되는 치환아미딘유도체 또는 그염 및 이 화합물을 함유하는 혈소판저해제인 것을 특징으로 한 것이다.
상기 일반식(1)로 표시되는 화합물은, 피브리노겐길항작용에 기초한 뛰어난 혈소판응집저해작용을 가지고, 특히 경구투여에서의 유효성에 뛰어나고, 혈전증, 경피경관관동맥형성시술후 또는 경피경관관동맥재개통시술후의 재협착 또는 재폐쇄의 예방 또는 치료에 유효하다.

Description

치환아미딘유도체 또는 그 약학적으로 허용되는 염 및 그것을 함유하는 혈소판응집저해제
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음

Claims (12)

  1. 일반식(1)
    [식 중, A는 -CON(R1)- 또는 -N(R1)CO-(R1은 수소원자 또는 탄소수 1~4의 알킬기를 표시함)을, D2, D3은 탄소원자를 표시하고, A는 D2또는 D3에 결합해 있다. B는 -CH2- 또는 -O-를 표시하고, X는 -CH- 또는 -N-을 표시함. 단, B가 -O-일 때, X는 -N-이 아니다. Z는 수소원자 또는 치환되어 있어도 되는 알킬기를 표시함. R2, R3, R4는, 수소원자, 탄소수 1~4의 알킬기, 프로파르길기, R5O(CO)- 또는 -CH2)m-Het(R5는 탄소수 1~4의 알킬기 또는 20메톡시에틸기, m은 1 또는 2를, Het는 피리딜기, 푸릴기 또는 티에닐기를 표시함)을, 또는 R2와 R3이 결합하고, 메틸렌 사슬의 임의의 위치가 탄소수 1~4의 알킬기 또는 탄소수 1~4의 알콕시기로 치환되어도 되는 -(CH2)n-W-(CH2)p-(n 및 p는 2 또는 3을, W는 결합, 또는 -CH2-, -O-, -N(R6)- 또는 -S(O)q-를, R6은 탄소수 1~4의 알킬기, 페닐기 또는 피리딜기를, q는 0, 1 또는 2를 표시함)을 표시함, 단 R2, R3, R4중 적어도 1개는, 수소원자, 탄소수 1~4의 알킬기, R5O(CO)-이외의 기로부터 선택된다]로 표시되는 것을 특징으로 하는 치환아미딘유도체 또는 그 약학적으로 허용되는 염.
  2. 제1항에 있어서, A가 D2에 결합해 있는 것을 특징으로 하는 치환아미드유도체 또는 그 약학적으로 허용되는 염.
  3. 제1항 또는 제2항에 있어서, R2와 R3이 결합해서 -(CH2)n-W-(CH2)p-이며, W가 결합, -CH2- , -O-, -S- 또는 -N(R6)인 것을 특징으로 하는 치환아미딘유도체 또는 그 약학적으로 허용되는 염.
  4. 제1항~제3항의 어느 한 항에 있어서, A가 NHCO- 또는 -CONH-인 것을 특징으로 하는 치환아미딘유도체 또는 그 약학적으로 허용되는 염.
  5. 제1항~제4항의 어느 한 항에 있어서, X가 CH-인 것을 특징으로 하는 치환아미딘유도체 또는 그 약학적으로 허용되는 염.
  6. 제1항~제5항의 어느 한 항에 있어서, B가 -CH2-인 것을 특징으로 하는 치환아미딘유도체 또는 그 약학적으로 허용되는 염.
  7. 제1항~제5항의 어느 한 항에 있어서, B가 O인 것을 특징으로 하는 치환아미딘유도체 또는 그 약학적으로 허용되는 염.
  8. 제1항~제4항의 어느 한 항에 있어서, X가 -N-인 것을 특징으로 하는 치환아미딘유도체 또는 그 약학적으로 허용되는 염.
  9. 제1항~제8항의 어느 한 항에 기재된 화합물 또는 그 약학적으로 허용되는 염을 유효성분으로서 함유하는 것을 특징으로 하는 혈소판응집저해제.
  10. 제1항~제8항의 어느 한 항에 기재된 화합물 또는 그 약학적으로 허용되는 염의 유효량을 투여하는 것으로 이루어진 것을 특징으로 하는 혈전증을 예방 또는 치료하는 방법.
  11. 제1항~제8항의 어느 한 항에 기재된 화합물 또는 그 약학적으로 허용되는 염의 유효량을 투여하는 것으로 이루어진 것을 특징으로 하는 경피경관관동맥형성시술후 또는 경피경관관동맥재개통시술후의 재협착을 예방 또는 치료하는 방법.
  12. 제1항~제8항의 어느 한 항에 기재된 화합물 또는 그 약학적으로 허용되는 염의 유효량을 투여하는 것으로 이루어진 것을 특징으로 하는 경피경관관동맥형성시술후 또는 경피경관관동맥재개통시술후의 재폐쇄를 예방 또는 치료하는 방법.
    ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
KR1019960037444A 1995-08-31 1996-08-31 치환아미딘유도체 또는 그 약학적으로 허용되는 염 및 그것을 함유하는 혈소판 응집저해제 Expired - Fee Related KR100225698B1 (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP22309495 1995-08-31
JP95-223094 1995-08-31

Publications (2)

Publication Number Publication Date
KR970010752A true KR970010752A (ko) 1997-03-27
KR100225698B1 KR100225698B1 (ko) 1999-10-15

Family

ID=16792745

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019960037444A Expired - Fee Related KR100225698B1 (ko) 1995-08-31 1996-08-31 치환아미딘유도체 또는 그 약학적으로 허용되는 염 및 그것을 함유하는 혈소판 응집저해제

Country Status (11)

Country Link
US (1) US5719145A (ko)
EP (1) EP0760364B1 (ko)
KR (1) KR100225698B1 (ko)
CN (1) CN1062266C (ko)
AT (1) ATE194829T1 (ko)
AU (1) AU686515B2 (ko)
DE (1) DE69609382T2 (ko)
DK (1) DK0760364T3 (ko)
ES (1) ES2149411T3 (ko)
NO (1) NO305654B1 (ko)
TW (1) TW363051B (ko)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4332384A1 (de) * 1993-09-23 1995-03-30 Merck Patent Gmbh Adhäsionsrezeptor-Antagonisten III
TW363051B (en) * 1995-08-31 1999-07-01 Mitsui Toatsu Chemicals Substituted amidine derivatives and platelet aggregation inhibitor containing the same
US6828275B2 (en) 1998-06-23 2004-12-07 Bayer Aktiengesellschaft Synergistic insecticide mixtures
EP0892044B1 (en) * 1997-07-18 2004-12-29 Mitsui Chemicals, Inc. Esterase and its use for the production of optically active chroman compounds
YU41801A (sh) 1998-12-14 2003-12-31 F. Hofman - La Roche Ag. Derivati fenilglicina
AU2097100A (en) 1998-12-16 2000-07-03 Boehringer Ingelheim Pharma Kg Substituted aryl and heteroaryl derivatives, their production and their use as medicines
EP1198231A1 (en) 1999-07-21 2002-04-24 American Home Products Corporation Bicyclic antagonists selective for the(alpha)v(beta)3 integrin
WO2012104866A1 (en) 2011-01-31 2012-08-09 Council Of Scientific & Industrial Research Chiral 1-(4-methylphenylmethyl)-5-oxo-{n-[(3-t-butoxycarbonyl- aminomethyl)]-piperidin-1-yl}-pyrrolidine-2-carboxamides as inhibitors of collagen induced platelet activation and adhesion

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0702671A4 (en) * 1993-06-09 1996-06-19 Smithkline Beecham Corp BICYCLIC FIBRINOGEN ANTAGONISTS
US5731324A (en) * 1993-07-22 1998-03-24 Eli Lilly And Company Glycoprotein IIb/IIIa antagonists
IL110172A (en) * 1993-07-22 2001-10-31 Lilly Co Eli Bicyclic compounds and pharmaceutical compositions containing them
US5629321A (en) * 1994-10-27 1997-05-13 Mitsui Toatsu Chemicals, Inc. Bicyclic compound and platelet aggregation inhibitor containing the same
TW363051B (en) * 1995-08-31 1999-07-01 Mitsui Toatsu Chemicals Substituted amidine derivatives and platelet aggregation inhibitor containing the same

Also Published As

Publication number Publication date
TW363051B (en) 1999-07-01
AU686515B2 (en) 1998-02-05
US5719145A (en) 1998-02-17
ES2149411T3 (es) 2000-11-01
CN1154962A (zh) 1997-07-23
EP0760364A3 (en) 1998-07-29
KR100225698B1 (ko) 1999-10-15
NO963469D0 (no) 1996-08-21
NO305654B1 (no) 1999-07-05
DE69609382T2 (de) 2001-03-08
CN1062266C (zh) 2001-02-21
ATE194829T1 (de) 2000-08-15
EP0760364A2 (en) 1997-03-05
NO963469L (no) 1997-03-03
EP0760364B1 (en) 2000-07-19
DK0760364T3 (da) 2000-10-09
DE69609382D1 (de) 2000-08-24
AU6217296A (en) 1997-05-08

Similar Documents

Publication Publication Date Title
ATE228115T1 (de) Bizyklische fibrinogenantagonisten
ES2185307T3 (es) Inhibidores de la farnesil transferasa que tienen una estructura piperidinica y procedimiento para su preparacion.
FI954609A0 (fi) 1-amidinofenyyli-pyrrolidoneja, -piperidinoneja ja -atsetinoneja verihiutaleiden kasaantumisen inhibiittoreina
DE122008000051I1 (de) 2-arylthiazolderivat sowie dieses enthaltendes arzneimittel
KR970701722A (ko) 포스폰산 디에스테르 유도체(phosphonic diester derivative)
KR950032180A (ko) 3-페닐피롤리딘 유도체
KR930007904A (ko) 방향족 아미딘 유도체 및 이의 염
ATE251146T1 (de) Selektive thrombin-hemmer
EP1666469A4 (en) INHIBITOR OF PLASMINOGENACTIVATORINHIBITOR-1
KR960704876A (ko) 혈소판 응집 저해 작용을 갖는 신규 화합물 (Novel Compound Having Platelet Aggregation Inhibitor Effect)
WO2001091738A3 (en) Naaladase inhibitors for treating amyotrophic lateral sclerosis
KR970010752A (ko) 치환아미딘유도체 또는 그 약학적으로 허용되는 염 및 그것을 함유하는 혈소판 응집저해제
PT1157998E (pt) Compostos heterociclicos seus intermediarios e inibidores da elastase
EP1142881A4 (en) POLY (ADP-RIBOSE) POLYMERASE INHIBITORS CONSISTING OF PYRIMIDINE DERIVATIVES
KR930703249A (ko) 인단유도체 및 이 화합물을 함유하는 트롬복산 길항제
EP0645382A4 (en) CUMARIN DERIVATIVES AND THEIR USE.
WO1998006400A3 (en) Pharmaceutical products for curing and preventing illnesses connected with the malfunction of vascular endothelial cells
DK0983765T3 (da) Forebyggende midler eller lægemidler mod sygdomme i forbindelse med vaskulær funktionel anomali i relation til insulinresistens
KR950703941A (ko) 일산화질소 합성 억제제(nitrogen monoxide synthesis inhibitor)
KR970701044A (ko) 콜린에스테라제 활성제
NO20020804L (no) Nye A-500359-derivater
EP1142875A4 (en) CINNAMAMIDE DERIVATIVES AND DRUG COMPOSITIONS THAT INCLUDE
DE69925225D1 (de) Propylaxe und behandlung der arzneimittel induzierten nierenstörungen
EP0660840A1 (en) PHOSPHONO SUBSTITUTED TETRAZOLE DERIVATIVES.
IE782005L (en) Pharmaceutical compositions

Legal Events

Date Code Title Description
A201 Request for examination
PA0109 Patent application

St.27 status event code: A-0-1-A10-A12-nap-PA0109

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

R17-X000 Change to representative recorded

St.27 status event code: A-3-3-R10-R17-oth-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

N231 Notification of change of applicant
PN2301 Change of applicant

St.27 status event code: A-3-3-R10-R13-asn-PN2301

St.27 status event code: A-3-3-R10-R11-asn-PN2301

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T13-X000 Administrative time limit extension granted

St.27 status event code: U-3-3-T10-T13-oth-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U11-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

PN2301 Change of applicant

St.27 status event code: A-5-5-R10-R13-asn-PN2301

St.27 status event code: A-5-5-R10-R11-asn-PN2301

FPAY Annual fee payment

Payment date: 20020611

Year of fee payment: 4

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 4

LAPS Lapse due to unpaid annual fee
PC1903 Unpaid annual fee

St.27 status event code: A-4-4-U10-U13-oth-PC1903

Not in force date: 20030722

Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000

PN2301 Change of applicant

St.27 status event code: A-5-5-R10-R13-asn-PN2301

St.27 status event code: A-5-5-R10-R11-asn-PN2301

PC1903 Unpaid annual fee

St.27 status event code: N-4-6-H10-H13-oth-PC1903

Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

Not in force date: 20030722

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000